QUOTE AND NEWS
Forbes  Oct 20  Comment 
When Craig Ventor's startup Celera beat the US government's Human Genome Project to seqencing human DNA, pundits heralded a new era in medicine. New drugs would target precise molecular processes, and soon patiences would receive treatments...
Wall Street Journal  May 2  Comment 
Call it the $200 million mystery. Word of a crucial scientific study helped medical-services company Quest Diagnostics negotiate a nearly $200 million discount in its deal to acquire Celera Corp.
New York Times  Apr 29  Comment 
The battle highlights not just the possibility of hedge fund interference in M.&A. transactions, the Deal Professor says, but also the dangers of using a tender offer in a bid challenged by shareholder activists.
Wall Street Journal  Apr 18  Comment 
Celera agreed to lower the breakup fee and amend other terms of its sale to Quest Diagnostics to settle lawsuits filed in Delaware and California.
Stock Blog Hub  Apr 15  Comment 
Leading diagnostics player, Quest Diagnostics (DGX) took a step forward toward the proposed acquisition of Celera Corporation (CRA). The company recently announced that the waiting period under the HSR Act has expired, though some other conditions...
StreetInsider.com  Apr 7  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Shareholder+Doesn%27t+Believe+Celera%27s+%28CRA%29+Royalty+Interests+Fully+Realized+in+Quest+%28DGX%29+Merger/6416744.html for the full story.
StreetInsider.com  Mar 28  Comment 
Visit StreetInsider.com at http://www.streetinsider.com/Corporate+News/Quest+Diagnostics+%28DGX%29+Launches+Tender+for+Celera+%28CRA%29/6390656.html for the full story.
Wall Street Journal  Mar 23  Comment 
When a company is sold, taking sides can make all the difference. Celera investors might want to bear that in mind.
FierceBiotech  Mar 21  Comment 
Quest Diagnostics is snapping up Celera--along with its expertise in genetics and biomarkers--for $344 million in cash. "Our discovery and validation of new biomarkers has exceeded our capacity to commercialize them. Combining Celera's expertise...





 


References

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki